TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: ≥ 18 and ≤ 75 years, both male and female;~* Radical hepatectomy has been performed for hepatocellular carcinoma;~* The hepatocellular carcinoma has been confirmed by pathological examination;~* Barcelona clinic liver cancer(BCLC) stage A or B;~* Not receiving any preoperative anticancer drug;~* The liver and kidney function satisfies the following conditions within 15 days after surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic transaminase(ALT)\<3 upper limit of normal(ULN), total bilirubin≤2ULN, serum creatinine \<1.5 ULN;~* Other laboratory tests meet the following requirements within 15 days after surgery (excluding day 15): Hb≥9g/dl, platelet count≥60×109/L, absolute neutrophil count\>1.0×109/L;~* The expected survival time ≥ 12 weeks;~* The subjects volunteer to sign the informed consent.~Exclusion Criteria:~* Hepatocellular carcinoma patients who received non-radical hepatectomy;~* Non-hepatocellular carcinoma patients;~* Those with Child-Pugh C;~* Pregnant or lactating women;~* Those with active bleeding due to various reasons;~* Those with HIV infection or AIDS-associated diseases;~* Those with severe acute and chronic diseases;~* Those with severe diabetes;~* Those with serious infectious diseases;~* Those who can not take drugs by oral route;~* Drug abusers or those with psychological or mental diseases that may interfere with study compliance;~* Conditions that are considered not suitable for this study investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Huaier Granule group (Type: EXPERIMENTAL): Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.
- Bank-control group (Type: NO_INTERVENTION): Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis (RA) for at least 3 months prior to screening~* Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg/week for at least 3 months prior to screening, and have been on a stable MTX dose of 15 mg/week to 25 mg/week for at least 4 weeks prior to screening~* Have an active RA, as defined by disease activity with at least 6 swollen and 6 tender joints, at the time of screening and at baseline~* C-Reactive Protein greater than or equal to 1.0 mg/dL at screening~* No history of latent or active tuberculosis prior to screening~Exclusion Criteria:~* Other inflammatory diseases, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or lyme disease~* Treated with disease modifying agents (other than methotrexate)/systemic immunosuppressives (eg, D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, sulfasalazine, leflunomide, azathioprine, cyclosporine, mycophenolate mofetil) during the 4 weeks prior to first administration of study agent~* Received intra-articular (in the joint), intramuscular (in the muscle), or intravenous corticosteroids, including adrenocorticotropic hormone, during the 4 weeks prior to first administration of study agent~* Known allergy to human immunoglobulin proteins or other components of golimumab~* Received any commercial or investigational anti-tumor necrosis factor alpha therapy such as but not exclusively infliximab, golimumab, adalimumab or etanercept

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Placebo + Methotrexate (MTX) (Type: EXPERIMENTAL): Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
- Group II: Golimumab + Methotrexate (MTX) (Type: PLACEBO_COMPARATOR): Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer (tumor \> 2 cm).~* Estrogen receptor-negative or -weakly positive tumors (less than 50% of cells), as evaluated using IHC.~* Risk factors for developing anthracycline-induced cardiomyopathy.~Exclusion Criteria:~* Severe heart failure (NYHA Class III or IV) .~* Metastatic disease.~* LVEF \< 45%.~* Pregnant or breast-feeding patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of thyroid neoplasm or benign goiter~* Scheduled for BABA endoscopic or robotic thyroidectomy~Exclusion Criteria:~* Completion thyroidectomy~* Modified radical neck dissection~* Allergy history~* Stroke history~* Uncontrolled hypertension~* Uncontrolled diabetes~* Coagulopathy~* Severe cardiovascular disease~* Severe pulmonary disease~* Chronic kidney disease~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
- Ropivacaine with epinephrine injection (Type: EXPERIMENTAL): 1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: A baby will be included if she/he:~* is a singleton~* is breastfed at day 7 by her/his mother and her/his mother intends to continue breastfeeding for at least 6 months~* has a post-partum blood sample with a negative HIV-1 DNA PCR test result at day 7 (+/- 2 days)~* has received ART as part of PMTCT~and if the mother:~* has reached the local legal age for participating in medical research studies~* is shown to be HIV-1 infected (with or without HIV-2 infection) and is not eligible for HAART or is not taking HAART~* has received a perinatal antiretroviral prophylaxis during pregnancy and delivery,~* has a CD4 count above the threshold of HAART initiation in pregnant women according to the national recommendation in each site (minimum 230 cells/µL),~* resides within the study area and is not intending to move out of the area in the next year~* gives assent for the infant to participate and gives consent to participate~Exclusion Criteria:~* S/he presents clinical symptoms and/or biological abnormalities equal to or greater than grade II of the ANRS classification for adverse event on the day of enrolment~* S/he presents with serious congenital malformation(s)~* Her/his birth weight is lower than 2.0 kg~* Her/his antiretroviral prophylaxis is extending beyond day 7~* The mother has participated in the trial for a previous pregnancy~* S/he and her/his mother are participating in another clinical trial on the day of enrolment

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 9 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): infant peri-exposure prophylaxis with lopinavir/ritonavir
- 2 (Type: ACTIVE_COMPARATOR): infant peri-exposure prophylaxis with lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent;~* BMI \< 30 kg/m2;~* Age 18 - 42 (upon starting COH);~* \<3 prior ART cycles (IVF, ICSI and related procedures);~* Baseline (day 2-3 of cycling) FSH \<15 IU/L and E2 \<80 pg/mL;~* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids);~* Patients must have at least three retrieved oocytes.~Exclusion Criteria:~* Intramural uterine fibroids that distort the uterine cavity or polyps \>1 cm;~* Stage III or IV endometriosis (no endometriomas);~* Hydrosalpinges;~* History of past poor response to COH resulting in canceling ART;~* Use of thawed/donated oocytes;~* Use of thawed/donated embryos;~* Gestational carrier;~* Patients affected by pathologies associated with any contraindication of being pregnant;~* Hypersensitivity to study medication;~* Uncontrolled adrenal or thyroid dysfunction;~* History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;~* History of arterial disease;~* Patients with hepatic impairment (liver function tests \> 2x upper limits of normal);~* Patients with dermatologic disease;~* Patients with renal impairment (estimated creatinine clearance \<60 mL/min/1.73 m2);~* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;~* High grade cervical dysplasia;~* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages, wherein pregnancy developed to a minimum of a gestational sac on TVUS;~* Participation in a concurrent clinical trial or in another trial within the past 2 months;~* Use of concomitant medications that might interfere with the study evaluation;~* Pre-implantation genetic diagnosis/screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone SC (Type: EXPERIMENTAL): None
- Progesterone Tablets (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VA Integrated Medication Manager

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Practiced in primary care for at least two years~* Third year residents with two years of residency in internal medicine or family practice~* Do not have to be currently practicing~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Integrated Medication Manager (Type: EXPERIMENTAL): Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
- Standard EHR (Type: NO_INTERVENTION): Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug~* Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent~Exclusion Criteria:~* Any new or uncontrolled condition that could make the participant unsuitable for participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Prior Placebo Group of Study 004 (Type: EXPERIMENTAL): Participants who received placebo and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 milligrams per kilogram (mg/kg) patisiran intravenously (IV) once every 3 weeks (Q3W) up to 65.5 months.
- Prior Patisiran Group of Study 004 (Type: EXPERIMENTAL): Participants who received patisiran and completed parent study ALN-TTR02-004 (NCT01960348) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 66.9 months.
- Prior Patisiran Group of Study 003 (Type: EXPERIMENTAL): Participants who received patisiran and completed parent study ALN-TTR02-003 (NCT01961921) were enrolled to receive 0.3 mg/kg patisiran IV Q3W up to 61.4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dyslipidemia with hypertesion~* msSBP \< 180 mmHg~* msDBP \< 110 mmHg~* LDL-C ≤ 250 mg/dL~* Triglycerides \< 400 mg/dL~Exclusion Criteria:~* At Visit 3, BP difference SBP ≥20mmHg or DBP ≥10mmHg~* CK normal range ≥ 2 times~* Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)~* AST or ALT ≥ 2 times~* Uncontrolled diabetes mellitus (HbA1c≥9%)~* CLcr \< 30 mL/min/1.73m\^2~* K \> 5.5 mEq/L~* Other exclusion applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
- Group II (Type: ACTIVE_COMPARATOR): Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
- Group III (Type: ACTIVE_COMPARATOR): Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy confirmed diagnosis of non-alcoholic steatohepatitis (within past 12 months)~* Ages 10 yrs and older~* Must swallow tablets on a regular basis~* ALT level \>60 iu/L~Exclusion Criteria:~* Subjects with known hypersensitivity to cysteamine~* History, currently or within the past 3 months, of the following conditions:~* Pancreatitis~* Inflammatory bowel disease~* Malabsorption~* Unstable heart disease, e.g., myocardial infarction, heart failure, arrhythmias.~* Unstable diabetes mellitus~* Any bleeding disorder.~* Zollinger-Ellison syndrome~* Malignant disease~* Subjects whom maybe pregnant or have health issues that make it unsafe for them participate, or whose concomitant medical problems preclude them from committing to the study schedule.~* No specific NASH medical therapy for 3 months such as vitamin E, s-adenosyl methionine or metformin or other NAFLD study drugs.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cystagon-EC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years of age.~* Diagnosis of dyslipidemia.~* That treatment with the fixed-dose combination of rosuvastatin / ezetimibe is documented.~* Have security questioning on at least two occasions.~Exclusion Criteria:~* Subjects who has taken any other statins, fibrates, bile acid sequestrants, niacin (\> 500 mg) or inhibitors of PCSK9 concomitantly during treatment with rosuvastatin / ezetimibe.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A: Rosuvastatin /Ezetimibe fixed dose (TREZETE®) (Type: None): Rosuvastatin /Ezetimibe fixed dose (TREZETE®) Pharmaceutical Form: Tablets Dosage: 10 mg / 10 mg or 20 mg / 10 mg Administration way: Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Scheduled for non-emergent, hepatic surgery~* Presence of an appropriate target bleeding site (TBS) as defined by the protocol~Major Exclusion Criteria:~* Subject will be undergoing a laparoscopic hepatic procedure where the Hemostatic Patch will be delivered and applied through a trocar~* In subjects with documented history of cirrhosis, subject has uncorrected platelet count \<60,000 per mm³ as determined by laboratory tests performed immediately prior to surgery~* Subject has severe coagulopathy defined as INR \> 2.0~* Subject has Total Bilirubin \>2.5mg/dL~* Subject has an active local infection at the Target Bleeding Site~* Study procedure involves a liver transplant recipient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veriset Hemostatic Patch (Type: EXPERIMENTAL): Veriset Hemostatic Patch
- Fibrin Sealant (TachoSil®) (Type: ACTIVE_COMPARATOR): Fibrin Sealant (TachoSil®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete